We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK-AUTHORIZED GENERIC PAXIL SLASHES APOTEX'S SALES
Apotex’s generic version of GlaxoSmithKline’s antidepressant Paxil (paroxetine HCl) garnered sales of only about $150 million to $200 million during its 180-day exclusivity period — a return far smaller than what it had expected because of an authorized generic competitor.